Thursday, November 28
While new-age tech IPOs are often launched with fanfare and lofty expectations, the post-listing reality has been far less glamorous. Nearly half of these companies that went public so far have seen their stock prices falter, trading below the post listing price, according to an analysis by ETMarkets.Out of 11 new-age technology companies that made their way on to the D-Street, 5 of them have yielded negative returns for investors, even after an extended post-listing period. This contrasts with the listing gains as 9 out of the 11 companies delivered positive returns to investors on debut.<iframe title="New-Age Tech IPOs: A Mixed Bag" aria-label="Table" id="datawrapper-chart-hPENk" src="https://et-infographics.indiatimes.com/graphs/hPENk/1/" scrolling="no" frameborder="0" style="width:
The mutual fund expert believes that a strategic allocation of 10-20% in the pharma and healthcare funds could benefit investors with a moderate to long term investment horizon because in the long term as healthcare demands continue to rise due to various factors, the sector may offer solid returns. “In the long term, as healthcare demand continues to rise due to demographic shifts, lifestyle diseases, and advancements in medical technology, the sector may offer solid returns. A 10-20% strategic allocation in these funds could benefit investors with a moderate-to-long-term investment horizon,” said Abhishek Jain, Head of Research, Arihant Capital.Pharma and healthcare sector based mutual funds have offered around upto 44% in 2024 so far. There were around 13 funds in the category which
